Olympus Acquires Stryker OP-1 Products, Spawns Biotech Division
This article was originally published in The Gray Sheet
Executive Summary
Olympus Corp. is forming a new business focused on regenerative medicine product offerings following the Dec. 6 purchase of Stryker Biotech's OP-1 orthopedic bone protein business for $60 million.
You may also be interested in...
News In Brief
Industry guides on ethical distribution pacts. Stryker settles charges over OP-1 marketing. Terumo buys Onset Medical. More news briefs.
Stryker Bets $316 Million It Can Invigorate Orthovita's Biologics Biz
Stryker hopes its sales force heft can push Orthovita's line of synthetic orthobiologics into a better growth position while filling important competitive gaps.
Stryker Bets $316 Million It Can Invigorate Orthovita's Biologics Biz
Stryker hopes its sales force heft can push Orthovita's line of synthetic orthobiologics into a better growth position while filling important competitive gaps.